Aldeyra Therapeutics (ALDX) said Monday that the US Food and Drug Administration has accepted its resubmitted new drug application for its topical ocular reproxalab, a treatment for dry eye disease.
The company said the FDA has assigned a Prescription Drug User Fee Act date of April 2.
Aldeyra has also expanded its option agreement with AbbVie (ABBV), which was entered into in October and could give the latter a co-exclusive license to develop, manufacture and commercialize the drug candidate in the US.
If AbbVie exercises the option, Aldeyra will receive a $100 million upfront payment, plus up to $300 million in milestone payments.
The company said it would share profits from the commercialization of reproxalap in the US under a split of 60% for AbbVie and 40% for Aldeyra.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。